Department of Molecular Oncology, Sri Shankara Cancer Hospital and Research Centre, Bangalore, India. My academic work focuses on understanding how the immune system shapes cancer initiation, progression, and therapeutic resistance, with the long-term goal of designing immune-modulatory strategies that improve cancer treatment outcomes. I integrate molecular immunology, cancer biology, and translational research to bridge mechanistic discoveries with clinically relevant therapeutic innovations, particularly in gastrointestinal cancers, hepatocellular carcinoma, and virus-associated malignancies. I am driven by the need to address two major unmet challenges in oncology: therapy resistance and immune evasion. Through my research, I investigate how tumor-intrinsic pathways, viral infections, microbial metabolites, and the tumor microenvironment collectively influence immune responses and cancer progression. This motivation stems from my training across diverse biological systems—from bacterial pathogenesis and metabolism to viral immunology and cancer therapeutics—which has shaped my systems-level approach to disease biology. What differentiates my work is its interdisciplinary breadth and translational depth. I uniquely combine expertise in host–pathogen interactions, cancer immunology, and therapeutic development, allowing me to identify unconventional regulatory pathways and repurpose them for clinical benefit. My contributions range from defining immune and metabolic mechanisms underlying platinum resistance, hepatocarcinogenesis, and COVID-19 pathology, to advancing novel therapeutic strategies such as mRNA vaccines, CAR-T cell optimization, and combinatorial targeted therapies. As an independent investigator, I actively translate fundamental discoveries into potential clinical applications, supported by international funding, patented innovations, and sustained leadership in collaborative research. Overall, my academic influence lies in connecting immunological mechanisms across cancer, infection, and metabolism, and in advancing innovative, immune-centered therapeutic strategies that move beyond conventional paradigms to improve patient outcomes. I have made sustained academic contributions to the fields of cancer immunology, viral oncology, host–pathogen interactions, and translational therapeutics, reflected through peer-reviewed publications, international scientific presentations, funded research leadership, and professional service. I have published over 30 peer-reviewed research articles in leading international journals, including Molecular Therapy, Hepatology, Journal of Virology, PLOS Pathogens, npj Vaccines, Cell Death & Disease, Free Radical Biology & Medicine, Clinical Translational Oncology, and Frontiers in Immunology. Importantly, more than a dozen of these publications are as first author and/or corresponding author, demonstrating independent intellectual leadership and sustained scholarly impact. Several of my publications are top-highlighted articles, cited in NIH COVID-19 treatment protocols, and included in Nobel Prize–related thematic collections (2023). My research outputs have received substantial international citations, reflecting consistent influence across oncology, immunology, virology, and metabolism research domains.